Jonathan Royce joins Bio-Works AB as CEO
July 3, 2020 / The Bio-Works Team
This week, Jonathan Royce assumed the role of chief executive officer of Bio-Works Sweden (BIOWKS.ST). He comes most recently from a role as Director of Instruments at Vironova AB and has a background in senior leadership roles within large-scale suppliers to the biopharmaceutical market including Millipore (now Merck-Millipore) and GE Healthcare Life Sciences (now Cytiva).
"With deep industry experience and a proven track record of performance, Jonathan is the right leader to lead Bio-Works into the future as an innovator in downstream purification," said Peter Ehrenheim, chairman of the Bio-Works Board of Directors. "We're confident Jonathan will take Bio-Works forward with a focus on furthering the company’s commercial success."
"We also want to thank Mats Johnson for his leadership as CEO during the past three years. Mats has built a strong foundation upon which Bio-Works can continue to grow," concluded Ehrenheim.
Royce, 43, has served in various senior leadership roles within several large-scale suppliers to the biopharmaceutical market including Millipore (now Merck-Millipore) and GE Healthcare Life Sciences (now Cytiva). During his 11-year tenure at GE, he led teams in global marketing of the bioprocessing portfolio, and global product management of the chromatography resins business. He has most recently held the role of Director of Instruments at Vironova AB, a Swedish biotech company focused on the viral vector market.
"I'm honored to lead the talented people of Bio-Works. Working together, we will strengthen our culture, continue to innovate and build trust with customers and collaborators," said Royce. "With the strength of our team and product portfolio, I'm confident in the future of Bio-Works."